SCHEMBL17599322

SCHEMBL17599322

Cc1c(S(=O)(=O)Nc2ccc(-c3cccc(C(=O)O)c3)c3ccccc23)cnn1-c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CCKBR P32239 1/20 0.48
TDP1 Q9NUW8 2/20 0.42
KMT2A Q03164 1/20 0.41
BRD4 O60885 3/20 0.41
DGAT2 Q96PD7 1/20 0.40
MCL1 Q07820 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
KDM5A P29375 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
KDM5B Q9UGL1 1/20 0.39
ACLY P53396 1/20 0.39
RAD52 P43351 1/20 0.39
TP53 P04637 1/20 0.39
FABP4 P15090 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17599392 0.85 CCKBR (0.47) CCKBRTDP1NPC1RAB9AACLY
SCHEMBL17599398 0.84 BRD4 (0.41) TDP1KMT2ABRD4MCL1ACLY
SCHEMBL17599350 0.84 LMNA (0.55) TDP1KMT2ABRD4MCL1ACLY
SCHEMBL17599325 0.84 TDP1 (0.39) CCKBRTDP1KMT2ABRD4MCL1
SCHEMBL17599365 0.84 TDP1 (0.41) TDP1KMT2ABRD4MCL1ACLY
SCHEMBL17613352 0.83 BRD4 (0.40) TDP1KMT2ABRD4MCL1ACLY
SCHEMBL17599403 0.77 WDR5 (0.49) TDP1KMT2ABRD4MCL1ACLY
SCHEMBL17599351 0.77 KMT2A (0.45) TDP1KMT2ABRD4MCL1NPC1
SCHEMBL17599382 0.77 WDR5 (0.45) TDP1KMT2AMCL1ACLYFABP4
SCHEMBL17599388 0.77 ACLY (0.48) TDP1KMT2ABRD4MCL1ACLY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2998294-A1 Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SANOFI (FR) 2016-03-23 EP disclosed
EP-2998294-A1 Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SANOFI (FR) 2016-03-23 EP disclosed